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Influence of diabetes and perivascular allogeneic
endothelial cell implants on arteriovenous fistula
remodeling
Michael S. Conte, MD,a Helen M. Nugent, PhD,b Peter Gaccione, MA,b
Prabir Roy-Chaudhury, MD, PhD,c and Jeffrey H. Lawson, MD, PhD,d San Francisco, Calif; Cambridge,
Mass; Cincinnati, Ohio; and Durham, NC
Objectives: Arteriovenous fistula (AVF) is the preferred type of vascular access for hemodialysis to treat end-stage renal
disease. A high proportion of AVF are never used for dialysis because the vein fails to mature adequately. We have
previously described the safety and feasibility of Vascugel (Genzyme BioSurgery, Cambridge, Mass) (allogeneic aortic
endothelial cells in a gelatin matrix) when placed around the anastomotic and venous outflow sites of AVFs (Vascular
intimal Hyperplasia: Extending Arterial and venous patency, Limiting vascular Trauma, and inhibiting Hyperplasia while
re-establishing vascular health [V-HEALTH] clinical study). In this retrospective analysis, we investigated factors that
influenced AVF remodeling in patients from the V-HEALTH study.We hypothesized that providing healthy endothelial cells
and their secreted factors immediately after surgery could enhance venous remodeling in the setting of vascular injury.
Methods: Thirty-one AVF patients from the V-HEALTH study were randomized 2:1 to receive either Vascugel or control
matrices (placebo) at surgery and were followed for 24 weeks. Venous lumen diameter was measured by ultrasound at 1,
3, and 5 cm from the anastomosis. Vein remodeling (change in lumen diameter at 4, 12, and 24 weeks compared with
baseline diameter at 2 weeks) was analyzed using a multiple regression mixed model.
Results: The results indicated that diabetes was a significant, negative predictor of venous remodeling over the 24-week
study (P  .02). The model-predicted change in lumen diameter from 2 to 24 weeks was 0.7 mm in diabetic patients
(n 11) and2.4 mm in nondiabetic patients (n 15), a difference of 3.1 mm, 95% confidence interval [CI] (1.4-4.9),
P  .0014. Patient race, baseline vein diameter, and time post-AVF creation were also significant factors that affected
remodeling (P< .05). Compared with placebo, there was a strong suggestion that Vascugel treatment improved the rate
of venous enlargement in diabetic patients (P  .05). The model-predicted change in lumen diameter at 24 weeks was
1.9 mm for placebo-treated diabetic patients and 0.4 mm for Vascugel-treated diabetic patients, a difference of 2.3
mm, 95%CI (0.1-4.8), P .06, suggesting that treatment with Vascugel maymitigate the negative influence of diabetes
on AVF remodeling.
Conclusions:Diabetes negatively impacts AVF remodeling and targeted local therapy with perivascular, allogeneic endothelial
cells may ameliorate this effect. A phase II trial designed specifically to evaluate AVF remodeling is needed to determine if
Vascugel can increase AVF maturation and use and to support larger randomized trials. (J Vasc Surg 2011;54:1383-9.)
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iA major challenge in caring for patients undergoing
hemodialysis for end-stage renal disease (ESRD) is main-
taining a functioning vascular access. Arteriovenous fistulas
(AVFs) have lower rates of infection, thrombosis, and
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doi:10.1016/j.jvs.2011.05.005ccess-related expenditures compared with either synthetic
rafts or central venous catheters and therefore constitute
he preferred type of access.1 However, these advantages
re somewhat negated by the high proportion of AVFs that
re never used for dialysis because the vein fails to mature
dequately.2 A recent large randomized clinical trial inves-
igating the use of clopidogrel on AVFmaturation reported
ailure rates of 61.8% in the clopidogrel group and 59.5% in
he placebo group during an ascertainment period which
egan approximately between 120 and 150 days after fis-
ula creation.3 In addition to those that never mature,
elayed maturation of AVF results in the prolonged use of
ndwelling catheters for dialysis, with their associated risks
nd costs. Two important goals therefore are increasing the
roportion of AVF that mature adequately as well as reduc-
ng the time required for fistula maturation.
A key component of AVF maturation is adequate dila-
ion of the outflow vein. The factors that influence AVF
emodeling are poorly understood, however, the most
ommonly identified etiology for failure to mature (FTM)
s stenosis occurring at the juxta-anastomotic venous
ite.4,5 Previous studies have demonstrated that changes in
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November 20111384 Conte et alblood flow induce vascular remodeling and that the re-
sponse to flow changes is controlled by the endothelium.6-8
The vascular endothelium regulates local biology by pro-
ducing and supplying compounds that have the capacity to
regulate vascular physiology, such as heparan sulfate (HS)
and transforming growth factor-1 (TGF-1) among many
others.9,10 Upon damage to the vein during the creation of
an AVF, the endothelium is disrupted, and its subsequent
role in venous remodeling may be impaired. In view
of the importance of the endothelium in AVF matura-
tion, we developed gelatin wraps containing quiescent al-
logeneic endothelial cells (Vascugel; Genzyme BioSurgery,
Cambridge, Mass), which can be placed perivascular to
the anastomosis sites of AVFs or arteriovenous grafts
(AVGs). Recently, the feasibility and safety of Vascugel was
demonstrated in a multicenter, randomized, double-blind,
placebo-controlled phase I/II trials (Vascular intimal Hy-
perplasia: Extending Arterial and venous patency, Limit-
ing vascular Trauma, and inhibiting Hyperplasia while
re-establishing vascular health [V-HEALTH]) in which
Vascugel implants were placed around the anastomotic and
venous outflow sites of AVF and AV grafts.11
In the context of the current analysis, we believe that
the V-HEALTH study offers a unique opportunity to
investigate the paracrine role of endothelial cells (ECs) in
AVF remodeling. We hypothesized that Vascugel treat-
ment might influence positive AVF remodeling. In the
present study, we analyzed ultrasound measurements of
venous lumen diameter in AVF patients from the
V-HEALTH trial, with the goal of identifying factors that
may influence AVF remodeling and also to provide further
insight into the role of ECs in this process.
METHODS
Study design. A retrospective analysis was performed
on the 31 AVF patients that enrolled in the V-HEALTH
study from July 2006 to August 2007 at six participating
sites. Full details of the V-HEALTH trial are reported
elsewhere.11 Patients were randomized 2:1 to receive either
Vascugel or control matrices (placebo) immediately prior
to surgery, using a computer-generated permuted block
randomization. The institutional review board at each par-
ticipating site approved the protocol, and all study patients
provided written informed consent prior to enrollment.
Individuals undergoing placement of new upper extremity
fistulas were eligible for enrollment if they were currently
receiving maintenance therapy of ESRDwith hemodialysis.
Patients also underwent preoperative veinmapping to iden-
tify blood vessels in the upper extremities which were
suitable for AVF creation. Diabetic status was determined
by completing a medical history on all subjects enrolled in
the study.
Investigational product. Vascugel is composed of al-
logeneic aortic ECs cultured in a gelatin (Gelfoam) matrix.
The human ECs are isolated from the aorta of single
cadaver donors and tested extensively for endothelial cell
purity; biological function (assays for secretion of HS,
TGF-1 and fibroblast growth factor, uptake of acetylated Now-density lipoprotein as well the ability to inhibit cul-
ured smooth muscle cell proliferation), the presence of
acteria, fungi, known human pathogens, and other adven-
itious agents according to FDA proposed rules.12,13 The
ells are cryopreserved for later expansion and formulation
n gelatin sponges. Vascugel was supplied to the clinical
ites as sponges having dimensions of 1.0  4.0  0.3 cm.
rior to shipment to the clinic, in vitro cohorts of Vascugel
ponges were assayed for cell number, viability, and se-
reted levels of HS and TGF-1. Each sponge contained
pproximately 1.23  106 human aortic EC (90% viabil-
ty) secreting levels of 0.69  0.05 g/mL/d HS and
66 29 pg/mL/d TGF-1. Placebo sponges were pack-
ged identically and were of the same shape and size but
acked ECs.
Study procedures. Study patients underwent planned
reation of surgical AVFs using standard surgical and anes-
hetic techniques per practice of the local treating physi-
ians. Sponges were placed at the conclusion of the proce-
ure after all bleeding at the sites has been controlled and
mmediately before surgical closure. For all patients, im-
lant administration consisted of two sponges placed adja-
ent to the venous anastomosis and along the outflow vein,
xtending 5 cm from the anastomosis. The use of medica-
ions such as antibiotics, heparin, and antithrombotics was
t the discretion of the treating physician and not specified
n the protocol. Following surgery, patients were seen and
xamined at 2, 4, 12, and 24 weeks to evaluate patency and
enous remodeling. Vein remodeling was assessed by color-
ow duplex ultrasound at postoperative visits, with the first
easurement obtained at week 2. A duplex instrument
ith range-gated Doppler and transducer frequency of 7 to
.0 MHz or greater, (grayscale, color, pulsed-wave Dopp-
er capability) was used at each site. The imaging carrier
requency was at least 5.0 MHz and the Doppler carrier
requency was at least 3.0 MHz. High resolution b-mode
maging was utilized to accurately determine lumen diam-
ter measurements. Three separate transverse images were
btained at each location (1, 3, and 5 cm) from the toe of
he venous anastomosis. Two orthogonal diameter mea-
urements were obtained for each image (Fig 1). All lumen
iameter measurements were performed by a blinded inter-
entional radiologist provided by an independent core Im-
ging Laboratory (RadPharm, Princeton, NJ).
Statistical methods. The patency analyses were per-
ormed on the intent-to-treat population (ITT), which
ncluded all randomized AVF patients who received Vascu-
el or placebo. The remodeling analysis was performed on
subset of the ITT population with available ultrasound
ata. Vein remodeling was calculated as the absolute
hange (mm) in lumen diameter at 4, 12, and 24 weeks
rom the “baseline” diameter at 2 weeks after surgery.
emodeling was analyzed using a multiple regression
ixed model. Fixed model factors were location in the vein
ie, distance from the anastomosis), patient age, treatment
Vascugel or placebo), time post-AVF creation, diabetes,
atient race (black, Hispanic, American Indian/Alaskan
ative, or white) and gender, with patient as the random
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Volume 54, Number 5 Conte et al 1385effect. Baseline diameter (week 2) was a covariate, and
interactions tested included patient age and diabetes status,
treatment and time, diabetes status and treatment, diabetes
status and time, and diabetes status and treatment and time.
Other factors that were investigated and found not to
contribute significantly to the model-predicted data in-
cluded previous AVF in the index arm, blood pressure,
statin, and intraoperative heparin use. Patency rates were
described in a continuous fashion, from the day of AVF
placement until the day of intervention or abandonment
(an event) or the subject’s last day on study (censored).
Overall duration of patency was analyzed using the Kaplan-
Meier product limit method. Results were summarized
descriptively using Q25, median (95% confidence interval
[CI]), and Q75. All lumen diameter calculations and sta-
tistical analyses were performed using SAS software, version
9.1 (SAS Institute Inc, Cary, NC). All mean values are
presented  standard deviation, and all model-predicted
values are presented with 95% CI.
RESULTS
Patient population. A total of 31 AVF patients en-
rolled in the phase I/II V-HEALTH trial, of which 23
received Vascugel and eight received placebo. Randomiza-
tion was closer to 3:1 than to the target 2:1 due to several
placebo-assigned patients undergoing AVG placement
based on intraoperative findings after having been allocated
Fig 1. A, Schematic image of location of venous diameter mea-
surements obtained by ultrasound 1, 3, and 5 cm from the venous
anastomosis, in relation to the treatment zone with Vascugel. B,
Representative ultrasound images and corresponding orthogonal
measurements of three separate transverse images that were ob-
tained at each location (1, 3, and 5 cm) from the toe of the venous
anastomosis. All lumen diametermeasurements were performed by
a blinded interventional radiologist provided by an independent
core imaging laboratory. The estimated intraclass correlation co-
efficient for the readings was 0.97.to the planned AVF group. There were no statistically wignificant differences in baseline characteristics between
he Vascugel and placebo AVF groups (Table I). Diabetic
reatment (insulin injection and/or oral agents) was given
o 92% of Vascugel diabetic patients and 100% of placebo
atients during the course of the study. Heparin was ad-
inistered during the surgical procedure in 39% of Vascu-
el patients and in 38% of placebo patients. Ninety percent
f the AVFs were placed in the upper arm (brachioce-
halic). Four Vascugel patients and one placebo patient
ere excluded from the remodeling analysis due to missing
aseline lumen diameter measurements. Values for the
hree images and the two orthogonal measurements ob-
ained at each location 1, 3, or 5 cm from the anastomosis
ere averaged so that each location per time point was
epresented by one value.
Venous remodeling. Mean baseline (week 2) lumen
iameter measurements by venous location for non-
iabetic, diabetic, placebo, and Vascugel patients did not
iffer significantly and are shown in Table II in addition to
ctual, unadjusted 24-week lumen diameters and change
rom baseline. Modeling the venous lumen diameter
hange indicated that diabetes was a significant predictor of
able I. Baseline characteristics of AVF subjectsa
haracteristic
Vascugel
N  23
Placebo
N  8
atient age, years 53.2  17.9 57.8  18.1
ale, % 56.5 62.5
lack, % 34.8 25.0
ardiovascular disease, % 100 100
iabetes mellitus,b % 52.2 50
ody mass index, (kg/m2) 26.3  6.7 28.7  4.1
ystolic blood pressure
(mm Hg) 127.8  21.2 144.4  24.5
iastolic blood pressure
(mm Hg) 76.6  14.2 76.9  18.1
rior AV access in index armc
Prior AVG (%) 1 (4.3) 0
Prior AVF (%) 5 (21.7) 1 (12.5)
No prior access 18 (78) 7 (88)
ntithrombotic use, % 78.3 62.5
ntiplatelet use, % 60.9 62.5
nticoagulant use, % 52.2 50.0
tatin use, % 60.9 37.5
emoglobin, g/dL 13.3  1.9 13.9  1.7
emodialysis initiated before
AVF creation, % 100 100
tudy accessd
Forearm, % 2 (8.7) 1 (12.5)
Upper arm, % 21 (91.3) 7 (87.5)
VF, Arteriovenous fistula; AVG, arteriovenous graft.
No statistically significant differences observed in baseline characteristics
etween groups.
Similar to the total population, there were no statistically significant differ-
nces observed in baseline characteristics between diabetic groups.
One Vascugel AVF subject had two previous accesses, one AVG and one
VF.
Study patients underwent planned creation of surgical AVF per standard
ractice and guidelines of the local treating physicians. Upper arm AVF were
rachial-cephalic; forearm AVF were radial-cephalic.orse outcome of venous remodeling (P  .02, Fig 2,
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November 20111386 Conte et alTable III). Other significant factors affecting change in
lumen diameter during the study were baseline diameter,
time post-AVF creation, patient race (poorer remodeling
was observed in blacks compared with white, Hispanic and
American Indian/Alaskan Natives), and the interactions of
diabetic status with patient age and diabetic status with
time post-AVF creation (P  .05, Table III). The model-
predicted change in lumen diameter at the final 24-week
time point was 0.7 mm (95% CI 2.1-.7) in diabetic
patients and 2.4 mm (95% CI 1.1-3.8) in nondiabetic
Table II. Actual, unadjusted baseline (2-week) and 24-we
Treatment
Diabetic
status
2-week baseline
diameter, mmb
— Nondiabetic 5.3  1.5
— Diabetic 6.1  1.5
Placebo — 5.7  1.1
Vascugel — 5.6  1.6
Placebo Nondiabetic 6.1  1.3
Vascugel Nondiabetic 5.0  1.4
Placebo Diabetic 5.2  0.6
Vascugel Diabetic 6.4  1.6
aAll lumen diameter and change in diameter values are actual values average
bNo statistically significant differences observed between groups (t-test).
cFive of the 31 patients were excluded from the remodeling analyses due to
dP .02 compared with diabetic group (t-test).
eP.03 compared with Vascugel diabetic group (t-test).
Fig 2. Model-predicted change in venous diameter over the
course of the study in 26 arteriovenous fistula (AVF) patients from
the V-HEALTH study. Line graph depicts the model-predicted
rate of change in venous lumen diameter compared with baseline
(2 weeks). Diabetes was a negative predictor of postoperative
venous remodeling (P  .02). Values were adjusted for baseline
diameter, location in the vein (distance from anastomosis), patient
age, gender, race, treatment (Vascugel or placebo), and time
post-AVF creation. Non-diabetic patients had a statistically signif-
icant (P  .007) increase in lumen diameter at weeks 12 and 24
compared with all previous time points. There was no statistically
significant change in lumen diameter at any of the measured time
points in the diabetic patients.patients, a difference of 3.1 mm, 95% CI (1. 4-4.9), P  p0014, Table IV. Examination of treatment and diabetic
tatus revealed that compared with placebo, there was a
trong suggestion that Vascugel treatment improved the
ate of venous enlargement during the 24-week study in
iabetic patients (P  .05, Fig 3). The model-predicted
hange in diameter at 24 weeks was 1.7 mm (95% CI,
4.0-0.6) in placebo diabetic patients and3.0 mm (95%
I, 1.2-4.8) in placebo nondiabetic patients, a difference of
.7 mm, 95% CI (1.8-7.7), P  .003, (Fig 3, Table IV).
he model-predicted change in lumen diameter at 24
eeks was 0.4 mm (95% CI, 1.1-1.9) in Vascugel
iabetic patients and 1.9 mm (95% CI, 0.4-3.3) in Vas-
ugel nondiabetic patients, a difference of 1.4 mm, 95% CI
0.3-3.2), P  .10, (Fig 3, Table IV). Diabetics treated
ith Vascugel had a larger predicted increase in vein diam-
ter at 24 weeks than placebo-treated diabetics (a difference
f 2.3 mm, 95% CI (0.1-4.8), P  .06, Table IV),
uggesting that treatment with Vascugel may mitigate the
egative influence of diabetes on remodeling.
Patency. As reported previously, treatment with Vas-
ugel did not significantly prolong unassisted or assisted
in diametersa
Nc
24-week
diameter, mm
Change in diameter
(2-24 weeks), mm
15 7.7  3.1 2.4  2.1d
11 6.5  1.8 0.5  1.3
7 7.4  2.8 1.7  2.3
19 7.2  2.7 1.6  2.0
4 9.4  2.0 3.3  1.6
11 7.1  3.3 2.1  2.2
3 4.8  0.9e 0.4  1.0
8 7.3  1.5 0.8  1.3
r vein location and not adjusted for covariates.
g 2-week measurements.
able III. Venous lumen diameter change from 2 to 24
eeks: Tests of fixed effects
Effect P value
Baseline diameter .0001
Location in vein (1, 3, 5 cm) .699
Weeks post-AVF creation .0001
Patient age .624
Gender .751
Diabetic status .018
Patient race .043
Treatment (Vascugel or placebo) .084
Interaction, age:diabetes .045
Interaction, week:diabetes .003
Interaction, treatment:week .115
Interaction, treatment:diabetes .143
Interaction, treatment:diabetes:week .082
VF, Arteriovenous fistula.ek ve
d ove
missinrimary fistula patency compared with placebo.11 At 24
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Volume 54, Number 5 Conte et al 1387weeks, the primary patency rates for patients who received
Vascugel was 60% vs 62% for placebo. Assisted primary
patency rates were 96% vs 88% for Vascugel and placebo,
respectively. One AVF from each of the Vascugel (4%) and
placebo (12.5%) groups was abandoned during the 24-
week follow-up period. Because diabetic status negatively
impacted AVF remodeling, patency of the two treatment
groups was also analyzed in the diabetic subpopulation.
Primary patency rates for diabetic patients who received
Vascugel was 55% vs 22% for placebo (P  .094). Assisted
primary patency rates were 90% vs 75% for Vascugel and
placebo, respectively (P  .351). There was no statistically
significant difference in time to first dialysis use between
AVFs treated with Vascugel or placebo (13% of Vascugel
and 12.5% of placebo patients did not use their access
during the 24-week follow-up period).
DISCUSSION
The V-HEALTH trial was designed to evaluate the
safety and feasibility of allogeneic endothelial implants in
patients undergoing surgical access creation for hemodial-
ysis. An exploratory goal of the study was to analyze the
effects of the investigational product on venous remodeling
in AVF patients. Analysis of serial ultrasoundmeasurements
performed at 2, 4, 12, and 24 weeks demonstrated that
diabetes is a potent factor influencing changes in venous
lumen diameter following AVF creation. Baseline (2-week)
diameter was also a significant predictor of remodeling and
therefore was used as a covariate. The data also suggest that
perivascular endothelial implants mitigate the negative in-
fluence of diabetes on venous remodeling, a potentially
important and novel finding that merits further investiga-
tion.
Low patency rates and FTM remain significant and
persistent problems that limit the effectiveness of AVFs for
hemodialysis access. Recent data from the Dialysis Access
Consortium provide evidence to this effect from a multi-
center experience (failure rates reached 61.8% in the treat-
ment group and 59.5% in the placebo group).3 The high
Table IV. Model-predicted final (24-week) vein diameter
Treatment Diabetic status N
24-week
mm (
— Nondiabetica 15 8.1d (6
— Diabetica 11 5.0 (3
Placebob — 7 6.2 (4
Vascugelb — 19 6.8 (5
Placeboc Nondiabetic 4 8.7 (6
Vascugelc Nondiabetic 11 7.5 (6
Placeboc Diabetic 3 3.8e (1
Vascugelc Diabetic 8 6.1 (4
AVF, Arteriovenous fistula.
aDiabetic categories: predicted values were adjusted for baseline diameter, lo
bTreatment categories: predicted values are adjusted for baseline diameter,
cTreatment/diabetic categories: predicted values are adjusted for baseline d
dP  .002 compared with diabetic group.
eP  .002 compared with placebo nondiabetic group; P  .06 compared wrate of FTM observed in this trial provides a compelling brgument for additional efforts to identify interventions
nd treatments to enhance fistula maturation. The KDOQI
Kidney Disease Outcomes Quality Initiative) guidelines
nd “fistula-first” initiative seek to increase the proportion
f AVFs used for hemodialysis and reduce the dependency
n indwelling catheters. One of the unintended conse-
uences of a more aggressive policy toward AVF creation
as been an increase in the observed rate of FTM, likely
esulting from attempted AVF creation using veins of mar-
inal caliber and/or quality.14,15 This leads to an associated
ncrease in catheter-dependency time, additional interven-
ions to revise the access, and increased overall costs.
learly, the clinical and resource implications of FTM
ollowing AVF creation are significant, yet the problem is
oorly understood. Both arterial and venous enlargement
s required for successful maturation of AVF. AVF failure is
lso associated with vascular stenosis that typically occurs
ithin the first few centimeters of the anastomosis in ap-
roximately 20% to 40% of cases.16-18 Prior studies have
uggested that certain clinical and anatomic factors, includ-
ng patient age, race, gender, presence of coronary or
eripheral atherosclerosis, and baseline vein diameter may
e predictive of FTM.4,19-21
The incidence of diabetes mellitus is increasing and in
ost countries is the single most important cause for
SRD.22 Diabetic ESRD patients are affected not only by
iabetes-related complications but also from a number of
omorbidities, such as cardiovascular and infectious com-
lications.22 Diabetes has been identified as a negative
redictor of AVF patency and fistula maturation in some
tudies but not in others.19,20,23,24 Hayakawa and col-
eagues recently reported that diabetes, in addition to pa-
ient age and gender, was a risk factor for successful main-
enance of an initial permanent vascular access.25 These
esults were confirmed in a study byGheith et al where both
adial and brachial AVFs survived significantly longer in
ondiabetic than in diabetic patients.20 However, other
uthors have not found an independent association be-
ween diabetes and AVF function.19,24 Among the plausi-
change from baseline
eter,
I)
Change in diameter
(2-24 weeks), mm (95% CI)
P value
(2-24 weeks)
5) 2.4d (1.1-3.8) .001
4) 0.7 (2.1-0.7) .31
7) 0.6 (0.9-2.1) .43
0) 1.2 (0.0-2.4) .06
.5) 3.0 (1.1-4.8) .003
0) 1.9 (0.4-3.1) .01
0) 1.9e (4.1-0.3) .09
6) 0.4 (1.1-1.9) .55
in the vein, age, gender, race, treatment, and weeks post-AVF placement.
n in the vein, age, gender, race, diabetes, and weeks post-AVF placement.
r, location in the vein, age, gender, race and weeks post-AVF placement.
scugel diabetic group.and
diam
95% C
.7-9.
.5-6.
.8-7.
.6-8.
.8-10
.1-9.
.6-6.
.6-7.
cation
locatio
iametele biologic factors linking diabetes to AVF maturation,
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November 20111388 Conte et alimpaired endothelial function,26,27 increased oxidative
stress, altered matrix metabolism, and cell proliferation
responses have been linked to abnormal glucose homeosta-
sis in related areas of cardiovascular biology.28-30 All of
these mechanistic pathways are likely influenced by Vascu-
gel.
Multiple lines of evidence suggest that changes in vessel
size and wall thickness in response to abrupt alterations in
hemodynamic forces (flow, pressure) are an adaptive pro-
cess of biomechanical stabilization. Shear stress appears to
be the dominant force governing lumen caliber change,
whereas radial wall stress exerts a strong influence on wall
thickness. The endothelium, by its elaboration of multiple
secreted factors, is both a primary sensor and an effecter in
Fig 3. Model-predicted change in venous diameter over the
course of the study segregated by diabetes and treatment (Vascugel
or placebo) status. Line graph depicts the model-predicted rate of
change in venous lumen diameter compared with baseline (2
weeks) in diabetic and nondiabetic subjects.A,Vascugel treatment
was associated with a larger predicted gain in venous lumen diam-
eter compared with placebo at each of the measured time points
(P  .05) among the diabetic patients. B, There were no signifi-
cant differences by treatment in the nondiabetic patients. Values
were adjusted for baseline diameter, location in the vein, patient
age, gender, race and weeks post-arteriovenous fistula (AVF) cre-
ation. There were no statistically significant changes in lumen
diameter at any of the measured time points in the diabetic
placebo subgroup; all other groups had significant changes in
diameter over time (P  .05).determining the vascular response to injury and blood flow thanges.8,31-33 Relatively few studies have quantitatively
ssessed the changes in arterial and venous diameter over
ime, and their determinants, following AVF creation.
ammers examined brachial and radial artery remodeling
ollowing AVF creation and found acute and long-term
ncreases in arterial lumen diameter due to flow changes
nd shear stress.7 Wong found that venous diameter in-
reased by 56% one day after forearm fistula creation and
urther increased to 123% of control by 12 weeks.34 Cor-
ataux demonstrated that within the first week of AVF
reation, mean shear stress increased by 2.5 to fivefold
ccompanied by an 86% increase in venous diameter; by 12
eeks, diameter had increased by 179%.35 Several studies
uggest that maximal blood flow in successful AVF is
chieved within 4 to 12 weeks. Recently, we examined the
nfluence of baseline endothelial function, as measured
sing brachial artery flow-mediated dilation (FMD), on the
ubsequent remodeling of artery and vein post-AVF cre-
tion.36 In this study, we determined that there was a
ositive correlation between arterial and venous enlarge-
ent post-AVF, and positive remodeling was correlated
ith baseline brachial FMD measured in the ipsilateral
xtremity. In addition, a negative relationship between
iabetes and venous remodeling was observed in that co-
ort, and confirmed by findings in the current study.
There are a number of important limitations of this
tudy, including modest sample size that limits our ability
o model the factors determining venous enlargement.
ost-hoc comparisons between treatment groups in any
rial should be cautiously interpreted as hypothesis-
enerating only. An important study limitation was that a
rue baseline vein diameter was not obtained at the time of
VF creation, but was assessed at the 2-week visit. Based on
ata cited above, it is likely that the early and most dramatic
hanges in remodeling post-AVF creation were missed by
his study design. However, this design reflected a practical
ompromise in the clinical trial protocol given that not all
articipating investigators had access to high-resolution
ntraoperative ultrasound, and postoperative assessments
ere made to coincide with typical follow-up schedules. In
ddition, changes in arterial diameter as well as volume flow
ates, also critical drivers of successful fistula maturation,
ere not assessed by ultrasound in this study. Despite these
imitations, our results suggest that diabetes is a potent
actor influencing venous remodeling in AVFs. The use of
erivascular tissue-engineered endothelium offered us a
nique opportunity to study whether supplementing the
enous and anastomotic sites of AVF with exogenous en-
othelial cells and their associated factors could enhance
he ability of AVFs to adapt and remodel in response to
ow. The results presented here suggest that Vascugel may
ave beneficial effects on venous remodeling, particularly in
he high-risk diabetic population. A phase II study de-
igned specifically to obtain data on AVF remodeling is
eeded to determine if Vascugel can increase AVF matura-
ion and clinical use, and to support larger randomized
rials.
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